6ARP
Structure of a mutant Cetuximab Fab fragment
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | AUSTRALIAN SYNCHROTRON BEAMLINE MX2 |
Synchrotron site | Australian Synchrotron |
Beamline | MX2 |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2014-08-20 |
Detector | ADSC QUANTUM 315r |
Wavelength(s) | 0.9537 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 64.060, 83.070, 211.600 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 47.420 - 1.700 |
R-factor | 0.17284 |
Rwork | 0.172 |
R-free | 0.19707 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 1yy8 |
RMSD bond length | 0.012 |
RMSD bond angle | 1.556 |
Data reduction software | XDS |
Data scaling software | Aimless |
Phasing software | PHASER |
Refinement software | REFMAC (5.8.0158) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 47.420 | |
High resolution limit [Å] | 1.700 | |
Number of reflections | 124960 | 5833 |
<I/σ(I)> | 16.2 | 1.8 |
Completeness [%] | 99.7 | 95 |
Redundancy | 6.7 | 6.4 |
CC(1/2) | 0.999 | 0.675 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, HANGING DROP | 293 | 100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol |